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Abstract
Biallelic, partial loss-of-function mutations in GNRHR cause a wide spectrum of reproductive
phenotypes from constitutional delay of growth and puberty to complete congenital hypogo-
nadotropic hypogonadism. We studied the frequency of GNRHR, FGFR1, TAC3, and
TACR3 mutations in nine adolescent and young adult females with clinical cues consistent
with partial gonadotropin deficiency (stalled puberty, unexplained secondary amenorrhea),
and describe phenotypic features and molecular genetic findings of monozygotic twin broth-
ers with stalled puberty.
Two girls out of nine (22%, 95%CI 6–55%) carried biallelic mutations in GNRHR. The girl
with compound heterozygous c.317A>G p.(Gln106Arg) and c.924_926delCTT p.(Phe309-
del) GNRHR mutations displayed incomplete puberty and clinical signs of hypoestrogenism.
The patient carrying a homozygous c.785G>A p.(Arg262Gln) mutation presented with signs
of hypoestrogenism and unexplained secondary amenorrhea. None of the patients exhibited
mutations in FGFR1, TAC3, or TACR3. The twin brothers, compound heterozygous for
GNRHR mutations c.317A>G p.(Gln106Arg) and c.785G>A p.(Arg262Gln), presented with
stalled puberty and were discordant for weight, and the heavier of them had lower testoster-
one levels.
These results suggest that genetic testing of the GNRHR gene should be offered to ado-
lescent females with low-normal gonadotropins and unexplained stalled puberty or men-
strual dysfunction. In male patients with partial gonadotropin deficiency, excess adipose
tissue may suppress hypothalamic-pituitary-gonadal axis.
Introduction
During the last four years, the scientific community has witnessed significant advances in the
identification of high-impact genetic factors that determine the timing of puberty. Especially,
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the discovery of paternally inherited mutations in MKRN3 as a cause of precocious puberty
in both sexes, and mutations in IGSF10 in a significant proportion of patients with delayed
puberty are findings that direct diagnostics and enable early counselling and patient assurance
[1,2]. In both scenarios, while the initial timing of the onset and/or pace of pubertal progres-
sion deviates from the population mean, the endogenous puberty per se will be completed and
the reproductive capacity is intact. This is not the case in patients with congenital hypogonado-
tropic hypogonadism (CHH), a rare disease that refers to deficient central regulation of the
gonadal function, which typically manifests as absent or delayed puberty [3]. The diagnosis of
CHH is often challenging especially in patients with partial forms, due to the difficulty in dif-
ferentiating CHH from the constitutional delay of growth and puberty (CDGP) or functional
hypothalamic amenorrhea [4–7].
We have previously investigated the frequency of GNRHR mutations in a well-phenotyped
cohort of patients with CDGP [8], but did not find any patients with biallelic mutations. Simi-
lar findings were recently reported from Brazil [9]. We therefore anticipated that GNRHR
mutations leading to partial loss-of-function, such as p.(Arg262Gln) and p.(Gln106Arg)
[10,11] should be sought for in patients with clinical and biochemical signs of mild gonadotro-
pin deficiency, such as problems in the progression of puberty and/or maintenance of the
hypothalamic-pituitary-gonadal axis. In addition, the seminal paper by Caronia et al. [4] sug-
gested that mutations in genes implicated in CHH could explain a significant proportion
of patients presenting with hypothalamic amenorrhea. Indeed, the clinical presentation of
CHH in females is notably heterogeneous: 12% of patients had experienced isolated menses,
and up to 50% presented with some degree of breast development [9,12]. In males, biallelic
partial loss-of-function mutations in GNRHR are known to cause a wide spectrum of repro-
ductive phenotypes ranging from delayed puberty and CHH, to reversal and relapse of CHH
[11,13,14], although the role of environmental factors in modifying the phenotype has been
difficult to address.
Knowing the previously described phenotypic variability of patients with GNRHR muta-
tions, we hypothesized that a significant proportion of adolescent and young adult patients
presenting with signs of partial gonadotropin deficiency (manifesting as stalled puberty or
unexplained secondary amenorrhea) harbor biallelic GNRHR mutations. In addition, we
describe monozygotic twins with biallelic GNRHR mutations who were discordant for weight
and displayed fascinating temporal variation in their phenotype.
Patients and methods
Adolescent and young adult female patients (mean age at recruitment 21.2±1.85 years (range,
18.1–25.6 years)) visiting the Helsinki University Hospital Gynaecology outpatient clinic
(clinician E. H.) between Sep 2015 and Mar 2016 (6 patients) and Dec 2016 to Jan 2017 (3
patients) with findings suggesting partial gonadotropin deficiency, manifesting as stalled
puberty (i.e. low or normal gonadotropin levels associated with spontaneous onset of breast
development with lack of progression) or unexplained secondary amenorrhea, were asked to
participate in the study. Patients with factors favoring functional hypothalamic amenorrhea
(HA), i.e. weight fluctuation and excessive exercise, were included only, if the experienced
recruiting clinician did not find these factors to exclusively support the diagnosis of HA.
Eleven patients were asked to attend the study, of whom two refused to participate. Of the nine
patients enrolled, seven had primary amenorrhea and at least partial spontaneous breast devel-
opment, and two patients had secondary amenorrhea, and subsequent hormone replacement
therapy (HRT) induced menstrual bleeding. Three patients had a positive self-reported family
history of delayed puberty.
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In addition, two boys referred to the pediatric endocrine outpatient clinic for incomplete
puberty were enrolled. These patients were monochorionic, diamniotic twins born at gestation
week 34+5 from the mother’s first pregnancy. The pregnancy had been spontaneous and with-
out complications, except for a pathologic oral glucose tolerance test. Amniocentesis at gesta-
tion week 16+3 demonstrated normal 46,XY karyotype for both fetuses. The twins were born
with similar birth size: birth measures were 47.0 cm/ 2430 g (Twin A) and 47.5 cm/ 2525 g
(Twin B). The pubertal development of the mother had been normal, with menarche occurring
at 13 years of age; similarly, the father’s pubertal progression had been normal. There was no
known family history of infertility or anosmia.
Pubertal status and biochemical testing
The clinical features of the patients were assessed during the investigations of stalled puberty
in the tertiary care center, and their medical histories were obtained from the patient record.
Pubertal stage was assessed according to Tanner [15] and, in boys, the testes were measured to
the nearest mm with a ruler, and testicular volume (TV) was calculated by using the formula
TV = length x width2 x 0.52 [16]. Bone age was assessed by using the BoneXpert software [17].
Serum LH and FSH concentrations were measured using an electrochemiluminescence
immunoassay (Roche Diagnostics, USA). Serum testosterone concentrations were measured
using mass spectrometry (AB Sciex, Foster City, California, USA), serum estradiol concentra-
tions either using immunochemical assays (AutoDelfia, Perkin-Elmer, USA, or Immulite
2000, Siemens, Germany) or mass spectrometry (Siemens Healthcare Diagnostics, Germany),
inhibin-B levels using ELISA (Beckman Coulter, Inc. USA), and AMH levels using immunoas-
say (Immunotech, Beckman Coulter Ltd. (A79765)). The normal values for estradiol in pre-
menopausal females (starting from Tanner stage IV) are 15–350 pg/mL 3.767 (= 0.056 nM-
1.32 nM) as they depend on the phase of menstrual cycle [18]. In the GnRH stimulation test, a
100 μg rapid bolus of GnRH (Relefact, Hoechst, Frankfurt am Main, Germany) was adminis-
tered intravenously. Serum FSH levels were measured at 0 (immediately before the administra-
tion of GnRH), 30, 60, and 90 minutes, and serum LH levels at 0, 20, 30, and 60 minutes,
respectively. Female patients had been off estrogen therapy for at least one month before bio-
chemical testing. Ultrasound scans of the reproductive organs were performed by an experi-
enced gynecologist at each visit.
Molecular genetic analyses
Genomic DNA from saliva samples of the subjects and their relatives was extracted according
to manufacturer’s instructions (Oragene DNA-kit OG-500, DNA Genotek Inc., Ottawa,
Ontario, Canada). The coding exons and exon-intron boundaries of GNRHR, FGFR1, TAC3,
and TACR3, were PCR-amplified, the PCR products were purified with Illustra ExoProStar
treatment (GE Healthcare, Chicago, Illinois, USA), and bi-directionally sequenced using the
ABI BigDyeTerminator Cycle Sequencing Kit (v3.1) and ABI Prism 3730xl DNA Analyzer
automated sequencer (Applied Biosystems, Thermo Fisher Scientific, Waltham, Massachu-
setts, USA). The sequences were aligned and read with Sequencher 5.0 software (Gene Codes
Corporation, Ann Arbor, Michigan, USA). All primer sequences are listed in S1 Table. The
PCR conditions are available upon request. Monozygosity of the twin brothers was analyzed
by DNA profiling (DNA Diagnostics Centre Finland).
Statistics
The GNRHR genotype frequency estimates for normal population were calculated from avail-
able allele frequency estimates in GnomAD database [19] based on the assumption that
GNRHR mutations in adolescents and young adults
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Finnish population is in Hardy-Weinberg equilibrium. Since the Phe309del was not listed in
GnomAD at all, we used its allele frequency data from our previous work in patients with con-
stitutional delay of growth and puberty [8]. Fisher’s exact test was first used to compare the
ratio of each biallelic GNRHR mutation (homozygous Arg262Gln and compound heterozy-
gous Gln106Arg/Phe309del) in our series of 9 patients to the estimated genotype frequencies
at population level. Finally, we used multinomial probability to estimate the probability to
have two patients with rare biallelic GNRHR mutations among our series of nine patients.
P<0.05 was accepted to indicate statistical significance.
Ethics
The study had been approved by the Ethics Committee of the Hospital District of Helsinki and
Uusimaa. The participants and/or their guardians gave their written informed consents for the
genetic studies according to the Declaration of Helsinki.
Results
GNRHR mutations among adolescent and young adult females with
clinical and biochemical signs suggesting partial gonadotropin deficiency
All patients had originally been referred for investigations of partial puberty or secondary
amenorrhea at the age of 16.0–18.8 years. The clinical features of these patients are presented
in Table 1. In brief, none of them was underweight or persistently obese for their age (patients
#8 and #9 had presented with fluctuations in their weight but the weights had been stable and
within the normal limits already for few years before being remitted to the tertiary medical
center), Patient #5 reported a history of excessive exercise (competitive athlete), however she
also had a sister with delayed puberty but no history of excessive exercise. Patient #6 was on
L-thyroxine and was biochemically and clinically euthyroid. Thyroid function tests were per-
formed in 8/9 girls, anemia was ruled out in 7/9, and hyperprolactinemia and celiac disease in
5/9. All patients had some degree of breast development before HRT, although Tanner staging
was not available for patient #7 (Table 1). However, she had irregular menstruations for three
years before secondary amenorrhea at 16 years of age, consistent with partially functioning
HPG axis. Patient #8 had oligomenorrhea for three years before secondary amenorrhea at 15
years of age.
Genetic testing revealed biallelic GNRHR mutations in two of nine (22%) (95%CI, 6–55%)
female patients (Table 1). No mutations were found in FGFR1, TAC3, or TACR3.
A compound heterozygous c.317A>G p.(Gln106Arg) and c.924_926delCTT p.(Phe309-
del) mutation in GNRHR was found in patient #1. Her healthy parents were heterozygous
carriers (mother: c.924_926del CTT p.(Phe309del), father: c.317A>G p.(Gln106Arg)).
Patient #1 had thelarche at the age of 11–12 years and spontaneous breast development up to
Tanner stage M4-5. However, she had primary amenorrhea, and was referred to a tertiary
center at the age of 16.6 years. The laboratory measurements at the age of 16.6–17.2 years
(before estrogen treatment) showed constantly low estradiol (0.02 nmol/L), FSH 1.0–1.3 IU/
L and LH 0.3–0.7 IU/L levels. In GnRH stimulation test, at the age of 16.7 years, the peak
FSH (3.1 IU/L) and LH (5.9 IU/L) levels were indistinguishable from levels seen in patients
with constitutional delay of growth and puberty. At the age of 17.9 years, she initiated hor-
mone replacement therapy (HRT), which induced menarche at the age of 19.1 years. At the
age of 19.5 years the HRT was ceased, and, when measured four months later, her estradiol
level was low (0.019 nmol/L), although her basal FSH (2.4 IU/L) and LH (1.7 IU/L) levels
were normal, and GnRH-induced peak FSH (5.5 IU/L) and LH (18.1 IU/L) levels were
GNRHR mutations in adolescents and young adults
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pubertal. She had no spontaneous menstrual bleeding and ultrasound examination showed
that the uterus had diminished in size. These findings were consistent with partial gonado-
tropin deficiency.
Patient #7 was found to harbor a homozygous c.785G>A p.(Arg262Gln) mutation in exon
3 of GNRHR. Since the parents’ DNA samples were not available, we verified the normal copy
number of GNRHR exon 3 with qPCR analysis. This patient had spontaneous menarche at the
age of 13 years, three years of irregular spontaneous menstruations and secondary amenorrhea
at the age of 16.0 years. She was treated with oral contraceptives and HRT (latter from 19.7
years of age onwards). The HRT was discontinued at the age of 25.0 years. Thereafter she had
a single uterine bleeding. After one month of HRT cessation, the laboratory values of gonado-
tropin and sex hormones were normal: estradiol 0.32 nmol/L, FSH 3.9 IU/L, LH 3.4 IU/L, and
AMH 1.0 ug/L. However, with further HRT withdrawal, secondary amennorhea occurred, and
within six months she had slipped back to hypogonadal state. The ovarian ultrasound exami-
nation revealed low antral follicle count (3/0) which suited with the low AMH level (1.2 ug/L).
Moreover, her serum estradiol was undetectably low (< 0.07 nmol/L) without elevated basal
gonadotropin levels (FSH 4.5 IU/L and LH 3.2 IU/L). All these findings were consistent with
partial gonadotropin deficiency.
Table 1. Clinical characteristics and GNRHR genotypes in adolescent and young adult females with clinical and biochemical findings suggesting
partial gonadotropin deficiency.
Patient Reason for
referral/age
Family
historyof
delayed
puberty
Spontaneous
pubertaldevelopment
(Tanner stage)
Serum hormone
levelsa
Findings on brain
MRI/ pelvic
ultrasound
GNRHR genotype
FSH
(IU/L)
LH
(IU/L)
E2
(nmol/
L)
#1 1˚amenorrhea/
16.6
No M4-5P4 1.0–
2.5
0.3–
2.1
0.019b-
0.14
normal brain MRI/thin
endometrium
c.317A>G p.(Gln106Arg)
and c.924_926delCTT p.
(Phe309del)
#2 1˚amenorrhea/
16.0
No M3 4.7 4.2 0.15 normal brain MRI/thin
endometrium
normal
#3 1˚amenorrhea/
16.5
Yes M4P3 4.0–
5.4
1.9–
3.3
<0.02–
0.25
small pituitary/
prepubertal uterus
normal
#4 1˚amenorrhea/
17.8
Yes M3P4 5.0–
6.3
3.4–
4.6
0.14–
0.15
NA/thin endometrium normal
#5 1˚amenorrhea/
16.6
Yes M3P3-4 6.7 1.6 0.12 NA/thin endometrium normal
#6 1˚amenorrhea/
18.8
No M5P4 4.4–
5.0
5.6–
7.2
0.14–
0.32b
NA/thin endometrium normal
#7 2˚amenorrhea/
18.8
No Yesc 2.2–
7.7
1.2–
4.7
0.03–
0.32
NA/thin endometrium c.785G>A p.(Arg262Gln)d
#8 2˚amenorrhea/
18.2
No M5P4-5 0.1–
6.0
0.1–
1.1
0.04–
0.08
normal brain MRI/thin
endometrium, adult
size uterus
normal
#9 1˚amenorrhea/
16.5
No M2P2 0.2–
0.3
<0.1 0.02–
0.05
normal brain MRI/thin
endometrium, small
uterus
normal
asingle measurement or range
bmeasured by mass spectrometry
cTanner staging not available
dhomozygous mutation
https://doi.org/10.1371/journal.pone.0188750.t001
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Enrichment of biallelic GNRHR mutations among adolescents and
young adults presenting with signs of partial gonadotropin deficiency
We estimated the genotype frequencies for the homozygous Arg262Gln genotype and
Gln106Arg/Phe309del compound heterozygous genotype in the Finnish population by using
the allele frequencies available from the GnomAD database [19] and our previous work [8].
The respective estimated genotype frequencies at population level are 1:35426, and 1:75335.
The occurrence of each of these genotypes alone in our series of 9 patients indicated significant
enrichment as compared to population level estimates (P<0.0005 and P<0.0002, respectively).
The probability to have these two patients with biallelic GNRHR mutations among our series
of nine patients was estimated to be very low, approximately one to thirty-seven million.
Monozygotic twin brothers with stalled puberty and biallelic GNRHR
mutations
The brothers were referred to the Helsinki University Hospital Paediatric Endocrine outpa-
tient clinic for the assessment of puberty. They had no history of cryptorchidism or micrope-
nis, and their developmental milestones had been normal; nor were there signs of chronic
illnesses underlying their pubertal delay. They continued to grow with prepubertal growth
velocity (Fig 1A). Interestingly, their weights had started to deviate from 9.5 years (Fig 1B); at
the age of 14.5 years, twin A had been investigated for weight loss, but no underlying cause
had been identified. Since then, his BMI-for-age had remained relatively stable, whereas his
twin brother had continued to gain weight (Fig 1B).
The clinical and biochemical data of the twins are presented in Table 2. In brief, based on
the Tanner stage G2P2 and pubertal levels of LH, FSH and inhibin-B at the age of 16.3, the
boys were considered to have constitutional delay of growth and puberty, and watchful waiting
was commenced (Table 2). Due to poor spontaneous progression of puberty, however, GnRH
stimulation test was performed, and it revealed pubertal LH responses. Brain MRI scans were
normal, although Twin B had an incidental arachnoid cyst. A low-dose monthly testosterone
treatment increased height velocities in both boys (Fig 1A). Twin B, heavier of the boys, had
consistently lower serum testosterone levels (Table 2).
Fig 1. Growth charts of monozygotic twin brothers who presented with stalled puberty due to biallelic mutations in GNRHR
(c.317A>G p.(Gln106Arg) and c.785G>A p.(Arg262Gln)). A. Longitudinal growth of the brothers was practically identical. Note the
absence of pubertal growth spurt. B. The brothers were discordant for weight. The reference ranges for body mass index (BMI) were
modified from [20].
https://doi.org/10.1371/journal.pone.0188750.g001
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Genetic testing was performed at the age of 18.1 years. Both brothers harbored compound
heterozygous mutations in GNRHR; c.317A>G p.(Gln106Arg) and c.785G>A p.(Arg262Gln),
and their healthy parents were heterozygous carriers (mother: c.785G>A p.(Arg262Gln),
father: c.317A>G p.(Gln106Arg)). Monozygosity of the twins was confirmed with DNA
profiling.
The boys were commenced on testosterone treatment for CHH at the age of 18.1 years. At
the age of 19.1 years, laboratory data (27 days after previous exogenous testosterone (Sustanon)
injection), together with the enlarged testicular volume (from 4 mL to 7 mL), suggested rever-
sal of CHH in Twin A, who at this point had serum T and gonadotropin levels within adult ref-
erence range (Table 2). Also Twin B showed some testicular growth and rise in serum T and
gonadotropin levels, indicative of partially functioning HPG-axis. However, his testosterone
level was still clearly lower than his brother’s (Table 2).
Serum transaminases and lipid levels were measured in the clinical laboratory at the age
of 18.8 years and they were within the normal range in both patients; HDL-cholesterol level,
however, was slightly lower in twin B (1.72 mmol/L vs. 1.31 mmol/l in Twin A vs. Twin B).
The SHBG levels of the boys were measured at the age of 19.1 years and they were 32 nmol/l
(Twin A) and 24 nmol/l (Twin B). Using the Vermeulen formula [21], the calculated free tes-
tosterone levels were 0,479 nmol/l / 2.23% in Twin A; and 0.179 nmol/l / 2.29% in Twin B.
Discussion
We examined adolescents and young adults with stalled puberty or unexplained amenorrhea
for mutations in GNRHR, FGFR1, TAC3, and TACR3 genes. This study was sparked by
Table 2. Clinical and hormonal findings in two monozygotic twin brothers who presented with stalled puberty due to compound heterozygous
mutations in the GNRHR gene (c.317A>G p.(Gln106Arg) and c.785G>A p.(Arg262Gln)).
Age (years) Testis size (mL) Tanner stage LH (IU/L) FSH (IU/L) Testosterone (nmol/L) Inhibin B (ng/L)
16.3
Twin A 3.2 G2P2 2.3 2.6 1.7 119
Twin B 3.2 G2P2 1.9 1.8 0.7 103
16.8
Twin A 4.5 G2P2 2.3 (19.7/60’)a 2.3 (5.1/20’,30’)a 2.1 122
Twin B 3.6 G2P2 1.7 (19.3/60’) 1.9 (4.5/30’) 0.9 131
17.5b
Twin A 5.2 G3P3 1.9 2.4 4.2 NA
Twin B 4.9 G3P3 1.8 1.8 3.7 NA
18.0
Twin A 4.0 G3-4P3 1.6 2.0 2.4 NA
Twin B 4.5 G3P3 1.6 1.7 1.3 NA
18.5c
Twin A 5.0 G4P4 NA NA NA NA
Twin B 5.0 G4P4 NA NA NA NA
19.1c
Twin A 7.0 G5P5 3.4 6.8 21.5 88
Twin B 6.6 G4P4 2.8 4.0 7.8 88
As shown in Fig 1, the Twin B was heavier than his brother.
aThe values in parentheses are peak values / timings of peak values in the GnRH stimulation test
bThe values at 17.5 years of age are measured after 6 months of low-dose testosterone therapy
cThe boys received continuous testosterone therapy for hypogonadotropic hypogonadism from the age of 18.1 years onwards
https://doi.org/10.1371/journal.pone.0188750.t002
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previous works, which have demonstrated a wide phenotypic spectrum in females with CHH
and a putative role of CHH genes in the etiology of hypothalamic amenorrhea [4,9,12]. Herein,
we hypothesized that biallelic GNRHR mutations could be enriched among adolescent and
young adult females presenting with clinical and biochemical signs suggesting partial gonado-
tropin deficiency, and found statistical evidence to support this notion, since two patients in
our series of nine harbored biallelic mutations in GNRHR. The patient harboring a compound
heterozygous GNRHR mutation p.(Gln106Arg) and p.(Phe309del) had spontaneous breast
development, primary amenorrhea, low estradiol levels with low-normal gonadotropin levels
and normal pubertal LH response to GnRH stimulation. Her clinical presentation was in
accordance with a study showing that the p.(Gln106Arg) mutation decreases the binding of
GnRH on the receptor causing a partial loss-of-function [10]. Previous clinical evidence also
link this mutation to partial CHH: the p.(Gln106Arg) mutation has been described in a homo-
zygous state in a female patient with partial CHH [22], and in compound heterozygous state
in female patients with partial puberty [10,23]. Pitteloud et al. [24] have described a male
patient homozygous for the p.(Gln106Arg) mutation in GNRHR with a partial phenotype who
underwent reversal of hypogonadotropic hypogonadism, and a partial CHH phenotype was
described in a Brazilian male patient homozygous for this mutation [9]. Very recently the phe-
notypic spectrum associated to p.(Gln106Arg) mutation was expanded to polycystic ovarian
syndrome [25]. The p.(Phe309del) mutation has been described in a compound heterozygous
state together with a p.(Arg262Gln) mutation in a CHH reversal patient [26]. Our patient
with the homozygous p.(Arg262Gln) mutation presented with secondary amenorrhea associ-
ated with normal gonadotropin levels, and probably normal pubertal development. The p.
(Arg262Gln) mutation has previously been shown to impair signal transmission and cause a
partial loss-of-function of the GnRH receptor [10]. Accordingly, previously described patients
carrying homozygotic p.(Arg262Gln) mutations have partial CHH phenotypes [13,27], and we
have previously reported two Finnish patients with reversal of CHH carrying p.(Arg262Gln)
mutation in a compound heterozygous state [26]. Interestingly, Caronia et al. [4] found a het-
erozygous p.(Arg262Gln) GNRHR mutation in a patient with hypothalamic amenorrhea.
Taken together, phenotypic variability is an important theme among GNRHR mutation carri-
ers [11,14,28,29], and it would be important to replicate our results in other populations with
relatively high carrier frequency of GNRHR mutations [30]. In general, the partial puberty
phenotypes are problematic, because such patients might not be detected timely; the Finnish
puberty screen for example relies first on the development of breast tissue before the age of 13
years [31]. Indeed, slowly progressing puberty with primary amenorrhea may in ambiguous
cases be unnecessarily attributed to eating disorders or excessive physical training, and the
onset of sex hormone replacement is remarkably delayed. Importantly, the diagnosis of func-
tional hypothalamic amenorrhea should only be made after exclusion of pathologies [32,33]. It
may be argued that our two female patients with biallelic GNRHR mutations, to some extent,
resemble adult onset hypogonadotropic hypogonadism. To the best of our knowledge, there
are no systematic descriptions of females with this condition, contrary to its well-known con-
cept in males [34–36]. It should be noted that women with normosmic CHH, an underinvesti-
gated topic, are diagnosed on average about nine years later than our patients [12].
Our study sheds light on environmental factors in determining the CHH phenotype in
males. We describe the first monozygotic twin brothers carrying compound heterozygous
GNRHR mutations p.(Gln106Arg) and p.(Arg262Gln) who presented with stalled puberty, and
were concordant for height but discordant for weight, which is quite unusual for monozygotic
twins [37]. The twin with the higher BMI-for-age had constantly ~50% lower spontaneous
serum T levels than his brother, suggesting modification of the HPG axis by adipose tissue.
Alternative explanations for the difference in sex steroid levels appear unlikely, as the patients
GNRHR mutations in adolescents and young adults
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have lived together throughout their lives, had similar birth weights, and share the fundamen-
tal genetic and environmental factors potentially affecting the timing of puberty. At 19 years
of age, the boys were on testosterone treatment, and the difference in their weight and sponta-
neous serum T levels was further pronounced. Interestingly, the twin with the lower BMI-for-
age showed signs of reversal of CHH. It is tempting to speculate that changes in the metabolic
status of a patient with partial CHH contributes to the reversal of CHH, a phenomenon fre-
quently reported also in patients carrying biallelic GNRHR mutations [22,24,26,34]. Indeed,
obesity during adolescence modifies HPG-axis activity in boys without reproductive disorders
by increasing aromatization of androgens to estrogens and circulating estradiol, which is a
well-established negative regulator of gonadotropin secretion in pubertal boys [38–40]. This
obesity-related suppression of gonadotropin secretion provides a plausible explanation to
observed difference in testosterone levels, particularly as also free testosterone was lower in the
overweight twin.
We conclude that biallelic mutations in GNRHR are enriched among adolescents and
young adults presenting with clinical and biochemical signs of partial gonadotropin deficiency,
and our results suggest that genetic testing of GNRHR should be offered to adolescent females
with low-normal gonadotropins and unexplained stalled puberty or menstrual dysfunction. In
males, excess adipose tissue may suppress HPG axis in patients with partial form of gonadotro-
pin deficiency.
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